BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Argus Health
Express Scripts

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title: Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
Abstract:Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are inhibitors of leukotriene biosynthesis. These compounds inhibit the mammalian 5-lipoxygenase enzyme, thus preventing the metabolism of arachidonic acid to the leukotrienes. These compounds are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
Inventor(s): Atkinson; Joseph G. (Montreal, CA), Guindon; Yvan (Ile Bizard, CA), Lau; Cheuk K. (Pierrefonds, CA)
Assignee: Merck Frosst Canada, Inc. (Quebec, CA)
Filing Date:Feb 04, 1988
Application Number:07/152,215
Claims:1. A compound of the formula: ##STR12## wherein the substituents for a compound are selected from the following groups:

2. A compound of claim 1 which is: 117-133, 135-161, or 287.

3. A compound of claim 1 which is: 117, 126, 127, 132, 138, 146, or 154.

4. A compound of the Formula Ic: ##STR29## wherein R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, Ar.sub.1 --C.sub.1 to C.sub.3 alkyl, Ar.sub.1 or CH.sub.2 OH;

R.sub.3, R.sub.4 and T are each independently selected from:

(1) hydrogen;

(2) alkyl having 1 to 4 carbon atoms;

(3) alkenyl having 2 to 4 carbon atoms;

(4) --(CH.sub.2).sub.n M wherein

n is 0 or 1, and

M is

(a) --OR.sub.5 ;

(b) halogen;

(c) --CF.sub.3 ;

(d) --SR.sub.5 ;

(e) Ar.sub.1 ;

(f) --COOR.sub.6 ;

(g) ##STR30## wherein R.sub.12 is H, C.sub.1 to C.sub.6 alkyl, or Ar.sub.1 ; (h) ##STR31## (i) ##STR32## (j) ##STR33## (k) ##STR34## (l) NR.sub.8 R.sub.9 ; (m) --NHSO.sub.2 R.sub.10 wherein R.sub.10 is C.sub.1 to C.sub.6 alkyl, phenyl, p-tolyl or CF.sub.3 ;

(n) --SOR.sub.5 ;

(o) --CONR.sub.8 R.sub.9 ;

(p) --SO.sub.2 NR.sub.8 R.sub.9 ;

(q) --SO.sub.2 R.sub.5 ;

(r) k--NO.sub.2 ; or

(s) --CN;

or any two of R.sub.3, R.sub.4 and T may be joined to form a saturated ring having 5 or 6 ring atoms, said ring atoms comprising 0, 1 or 2 oxygen atoms, the remaining ring atoms being carbon;

each R.sub.5 is independently H, C.sub.1 to C.sub.6 alkyl, benzyl Ar.sub.1, perfluoro-C.sub.1 -C.sub.4 alkyl, CH.sub.2 --R.sub.11 wherein R.sub.11 is hydroxy C.sub.2 to C.sub.5 alkyl, CH.sub.2 COOR.sub.6, or CH.sub.2 CO--R.sub.7 ;

each R.sub.6 is independently H or C.sub.1 to C.sub.6 alkyl;

each R.sub.7 is independently C.sub.1 to C.sub.6 alkyl, benzyl, Ar.sub.1, NR.sub.8 R.sub.9, NHAr.sub.1, O--C.sub.1 to C.sub.4 alkyl;

each R.sub.8 and each R.sub.9 is independently H or C.sub.1 to C.sub.4 alkyl, or R.sub.8 and R.sub.9 may be joined through the N to which they are attached to form a heterocycloalkyl ring having 5 to 8 ring atoms;

each R.sub.13 is independently hydrogen, R.sub.8, R.sub.9, or Ar.sub.1, and

each Ar.sub.1 is independently 1- or 2-naphthyl, phenyl or mono- or disubstituted phenyl, wherein the substituents on the phenyl are independently selected from C.sub.1 to C.sub.3 alkyl, I, Br, Cl, F, COOR.sub.6, (CH.sub.2).sub.n --NR.sub.8 R.sub.9 wherein n is 0 to 2, methylenedioxy, C.sub.1 to C.sub.3 alkoxy, OH, CN, NO.sub.2, CF.sub.3, C.sub.1 to C.sub.4 acyl, NR.sub.8 R.sub.9, S--C.sub.1 to C.sub.6 alkyl, SO--C.sub.1 to C.sub.6 alkyl, and SO.sub.2 --C.sub.1 to C.sub.6 alkyl; with the proviso that at least one of the R.sub.13 groups in the Formula Ic is Ar.sub.1, and one of R.sub.3, R.sub.4 and T is OR.sub.5 or --OCOR.sub.7 ;

or a pharmaceutically acceptable salt thereof.

5. A method of inhibiting mammalian leukotriene biosynthesis or actin which comprises administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of claim 1.

6. A method of claim 5 wherein the mammal is a human.

7. A method of treating pulmonary conditions, inflammation, allergies, pain, cardiovascular conditions, or skin conditions which comprises administering to a human in need of such treatment a pharmaceutically effective amount of a compound of claim 1.

8. A pharmaceutical composition useful for inhibiting the biosynthesis of mammalian leukotrienes comprising a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: